Summit hits first milestone in Duchenne muscular dystrophy program
Nasdaq-listed Oxford spinout Summit Therapeutics has hit its first research milestone as part of a multiyear strategic alliance with the University of Oxford. The collaboration is focussed on developing future-generation utrophin modulators for the potential treatment of all patients with the progressive muscle wasting disorder Duchenne Muscular Dystrophy.